A phase 2 clinical trial of axitinib and avelumab in patients with recurrent/metastatic adenoid cystic carcinoma (ACC).

被引：0
|
作者：
Ferrarotto, Renata
Bell, Diana
Feng, Lei
Li, Kaiyi
Mott, Frank
Blumenschein, George R.
De Sousa, Luana Guimaraes
Altan, Mehmet
Marques-Piubelli, Mario L.
Dal Lago, Eduardo Andreazza
Kaya, Diana
Godoy, Myrna
Kupferman, Michael Elliot
Glisson, Bonnie S.
El-Naggar, Adel K.
Elamin, Yasir Y.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Thorac Head & Neck Med Oncol, Houston, TX USA
[2] City Hope Natl Med Ctr, Duarte, CA USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Biostatist, Houston, TX USA
[4] MD Anderson Canc Ctr, Houston, TX USA
[5] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[6] Univ Texas MD Anderson Canc Ctr, Dept Thorac & Head & Neck Med Oncol, Houston, TX USA
[7] Univ Sao Paulo, Sao Paulo, Brazil
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6019
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A phase II study of sunitinib in recurrent and/or metastatic adenoid cystic carcinoma (ACC) of the salivary glands: current progress and challenges in evaluating molecularly targeted agents in ACC
    Chau, N. G.
    Hotte, S. J.
    Chen, E. X.
    Chin, S. F.
    Turner, S.
    Wang, L.
    Siu, L. L.
    ANNALS OF ONCOLOGY, 2012, 23 (06) : 1562 - 1570
  • [32] A phase II study of axitinib (AG-013736) in patients with incurable adenoid cystic carcinoma
    Ho, A. L.
    Dunn, L.
    Sherman, E. J.
    Fury, M. G.
    Baxi, S. S.
    Chandramohan, R.
    Dogan, S.
    Morris, L. G. T.
    Cullen, G. D.
    Haque, S.
    Sima, C. S.
    Ni, A.
    Antonescu, C. R.
    Katabi, N.
    Pfister, D. G.
    ANNALS OF ONCOLOGY, 2016, 27 (10) : 1902 - 1908
  • [33] Phase II study of regorafenib in progressive, recurrent/metastatic adenoid cystic carcinoma.
    Ho, Alan Loh
    Sherman, Eric Jeffrey
    Baxi, Shrujal S.
    Haque, Sofia
    Ni, Ai
    Antonescu, Cristina R.
    Katabi, Nora
    Morris, Luc G.
    Chan, Timothy An-thy
    Pfister, David G.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [34] Clinical and histological prognostic factors of recurrent and/or metastatic salivary gland adenoid cystic carcinoma
    Lorini, L.
    Gurizzan, C.
    Tomasoni, M.
    Lombardi, D.
    Mattavelli, D.
    Paderno, A.
    Deganello, A.
    Ardighieri, L.
    Battocchio, S.
    Bozzola, A.
    Ravanelli, M.
    Maddalo, M.
    Zamparini, M.
    Magrini, S. M.
    Maroldi, R.
    Nicolai, P.
    Berruti, A.
    Bossi, P.
    ANNALS OF ONCOLOGY, 2020, 31 : S680 - S680
  • [35] A Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma
    Hanna, Glenn J.
    Ahn, Myung-Ju
    Muzaffar, Jameel
    Keam, Bhumsuk
    Bowles, Daniel W.
    Wong, Deborah J.
    Ho, Alan L.
    Kim, Sung-Bae
    Worden, Francis
    Yun, Tak
    Meng, Xianzhang
    Van Tornout, Jan M.
    Conlan, Maureen G.
    Kang, Hyunseok
    CLINICAL CANCER RESEARCH, 2023, 29 (22) : 4555 - 4563
  • [36] A phase II study of axitinib in patients with recurrent or metastatic nasopharyngeal carcinoma (NPC).
    Hui, Edwin Pun
    Ma, Brigette
    Mo, Frankie
    Kam, Michael K. M.
    Chan, Stephen Lam
    Loong, Herbert H. F.
    Ho, Rosalie
    Leung, Sing Fai
    King, Ann Dorothy
    Wang, Ki
    Ahuja, Anil Tejbhan
    Chan, Charles
    Hui, Connie W. C.
    Wong, Chi Hang
    Chan, Anthony T. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [37] A phase II study of lenvatinib plus pembrolizumab in patients with progressive, recurrent/metastatic adenoid cystic carcinoma.
    Mohamadpour, Maliheh
    Sherman, Eric Jeffrey
    Kriplani, Anuja
    Fetten, James Vincent
    Dunn, Lara
    Michel, Loren S.
    Hung, Kin Wai
    Baxi, Shrujal S.
    McDonald, Erin
    Conybeare, Rachel
    Katabi, Nora
    Ostrovnaya, Irina
    Pfister, David G.
    Ho, Alan Loh
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [38] A randomized phase II study of pembrolizumab with or without radiation in patients with recurrent or metastatic adenoid cystic carcinoma.
    Schoenfeld, Jonathan Daniel
    Mahmood, Umair
    Chen, Yu-Hui
    Mak, Raymond H.
    Lorch, Jochen H.
    Hanna, Glenn J.
    Sridharan, Vishwajith
    Bang, Andrew
    Busse, Paul Martin
    Willers, Henning
    Mamon, Harvey J.
    Yoo, Hyung-Jin
    Pai, Sara I.
    Wirth, Lori J.
    Haddad, Robert I.
    Chau, Nicole Grace
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [39] Alliance A091104: A phase II trial of MK-2206 in patients (pts) with progressive, recurrent/metastatic adenoid cystic carcinoma.
    Ho, Alan Loh
    Foster, Nathan R.
    Meyers, Jeffrey P.
    Vasudeva, Shyamprasad Deraje
    Katabi, Nora
    Antonescu, Cristina R.
    Pfister, David G.
    Horvath, Laura E.
    Erlichman, Charles
    Schwartz, Gary K.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [40] Second-line systemic therapy in patients with recurrent or metastatic adenoid cystic carcinoma
    Kadowaki, Shigenori
    Nakazawa, Taiko
    Ogata, Takatsugu
    Matsubara, Yuki
    Nozawa, Kazuki
    Kato, Kyoko
    Narita, Yukiya
    Honda, Kazunori
    Masuishi, Toshiki
    Bando, Hideaki
    Ando, Masashi
    Hanai, Nobuhiro
    Muro, Kei
    ANNALS OF ONCOLOGY, 2021, 32 : S312 - S312
12345